Trial Profile
A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Solasia Pharma
- 08 Feb 2021 The study protocol was revised to add one more dosage regimen, 300 mg/m2/day for 5 consecutive days followed by a 16-day rest in 3-week cycles (dose-schedule 3), as per results published in the Japanese Journal of Clinical Oncology
- 08 Feb 2021 Results of pooled analysis from trials (NCT01435863 and NCT01689220) published in the Japanese Journal of Clinical Oncology
- 08 Dec 2015 Pooled results (n=23) of this and other trial (see profile 223385) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology